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Introduction
The actins are a highly conserved protein family (89% identity 
between cytoskeletal actin in yeast and -actin in humans; 
Sheterline et al., 1998) that play crucial roles in cell biology, 
in division, motility, the cytoskeleton, and contraction. Higher 
eukaryotes have six different actins, each expressed from sep-
arate genes (Vandekerckhove and Weber, 1978), with most 
variability between the proteins occurring at their N termini 
(Fig. S1). - and -actin are almost ubiquitously expressed 
and  form  the  actin  cytoskeleton.  Smooth  muscles  express 
smooth muscle -actin and enteric -actin, whereas striated 
muscles express predominantly cardiac -actin and skeletal 
muscle -actin, so named after the adult tissues in which they 
are abundantly found.
All isoforms, except enteric -actin (GenBank/EMBL/DDBJ 
accession no. NM_001615), are known to be associated with 
human diseases. Mutations in cytoplasmic -actin (ACTB; 
GenBank/EMBL/DDBJ accession no. NM_001101; OMIM no. 
102630) can cause neutrophil dysfunction, mental retardation, 
and recurrent infection (Nunoi et al., 1999) or developmental 
malformations, deafness, and dystonia (Procaccio et al., 2006), 
whereas mutations in cytoplasmic -actin (ACTG1; GenBank/
EMBL/DDBJ accession no. NM_001614; OMIM no. 102560) 
cause deafness (Zhu et al., 2003). Mutated cardiac -actin (ACTC; 
S
keletal muscle -actin (ACTA1) is the major actin 
in postnatal skeletal muscle. Mutations of ACTA1 
cause mostly fatal congenital myopathies. Cardiac 
-actin (ACTC) is the major striated actin in adult heart 
and fetal skeletal muscle. It is unknown why ACTC and 
ACTA1 expression switch during development. We in-
vestigated whether ACTC can replace ACTA1 in post-
natal skeletal muscle. Two ACTC transgenic mouse lines 
were crossed with Acta1 knockout mice (which all die by 
9 d after birth). Offspring resulting from the cross with 
the high expressing line survive to old age, and their 
skeletal  muscles  show  no  gross  pathological  features. 
The mice are not impaired on grip strength, rotarod, or 
locomotor activity. These findings indicate that ACTC is 
sufficiently similar to ACTA1 to produce adequate func-
tion in postnatal skeletal muscle. This raises the prospect 
that  ACTC  reactivation  might  provide  a  therapy  for 
ACTA1 diseases. In addition, the mouse model will allow 
analysis  of  the  precise  functional  differences  between 
ACTA1 and ACTC.
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only 4 aa (Fig. S1). Although the precise role of these amino 
acid differences is not known, they are conserved from birds to 
humans (Kumar et al., 1997), and it has been postulated that 
these differences are crucial for function in their respective adult 
tissues (Rubenstein, 1990).
We hypothesized that if ACTC, a fetal striated actin iso-
form in skeletal muscle, could functionally replace ACTA1 in 
postnatal muscle, perhaps ACTC could be used in a therapeutic 
approach for patients with currently incurable ACTA1 myo-
pathies. We recently demonstrated similar ACTC levels in extra-
ocular muscles to those in the heart and postulated that this 
underlies (at least in part) the lack of ophthalmoplegia and 
cardiomyopathy in even the most severely affected patients with 
ACTA1 mutations (Ravenscroft et al., 2008). However, if the 
4 aa by which ACTA1 and ACTC differ (Fig. S1) are crucial to 
postnatal skeletal muscle function, altering the proportions of 
each in muscle might be deleterious in itself.
Acta1 knockout (KO) mice die by postnatal day 9 (Crawford 
et al., 2002). To investigate the interchangeability of the two almost 
identical striated actin isoforms, ACTA1 and ACTC, and the im-
portance of their alternating developmental expression, we tested 
whether ACTC could functionally replace ACTA1 in developing 
and adult skeletal muscle and rescue Acta1 KO mice. We sought to 
establish through these experiments whether ACTC might be har-
nessed as a therapy for patients with ACTA1 disease. We show that 
ACTC can sufficiently replace ACTA1 in postnatal mouse skeletal 
muscle to allow survival to adulthood, justifying future investiga-
tion of ACTC as a therapeutic target for ACTA1 diseases.
Results
Increased ACTC expression in postnatal 
skeletal muscle was not deleterious
Two transgenic mouse lines, ACTC
Co and ACTC
Cr, designed to 
express the human ACTC cDNA in postnatal skeletal muscle were 
created. Fluorescent in situ hybridization showed that the trans-
gene was inserted into an autosome in the ACTC
Cr line and into 
the  X  chromosome  in  the  ACTC
Co  line  (unpublished  data). 
Breeding results confirmed that male ACTC
Co mice bred with 
wild-type females never gave rise to ACTC
Co male offspring.
Male ACTC
Co mice expressed significantly more ACTC 
compared with wild-type mice in all postnatal skeletal muscles 
tested by immunostaining (Fig. 1 A), Western blotting (740 ± 60%; 
P < 0.001; Fig. 2 A), and flow cytometry (not depicted). ACTC
Cr 
mice had a small but not significant increase in ACTC expres-
sion (110 ± 22%; P > 0.05; Figs. 1 A and 2 A). Histology, electron 
microscopy, and maximum specific force (measured by skinned 
fiber and whole-muscle contractility; unpublished data) demon-
strated that skeletal muscle from ACTC
Cr and ACTC
Co mice 
was  similar  to  wild-type  (C57BL/6;CBA/Ca  background, 
with no transgene) skeletal muscle. Therefore, the presence 
of ACTC in postnatal and adult skeletal muscle did not cause 
any deleterious effects. Dual-label immunohistochemistry on 
ACTC
Co quadriceps (Fig. 1 B) and other muscles (not depicted) 
for different myosin fiber types and ACTC showed that ACTC 
was predominantly expressed in myosin heavy chain (MHC) 
IIB fibers.
GenBank/EMBL/DDBJ accession no. NM_005159; OMIM no. 
102540) causes dilated (Olson et al., 1998) or hypertrophic 
cardiomyopathy (Mogensen et al., 1999). Mutations in smooth 
muscle -actin (ACTA2; GenBank/EMBL/DDBJ accession 
no. NM_001613; OMIM no. 102620) cause thoracic aortic 
aneurysms and dissections (Guo et al., 2007). However, the most 
disease-causing mutations, >170, have been identified in skeletal 
muscle -actin (ACTA1; GenBank/EMBL/DDBJ accession no. 
NM_001100; OMIM no. 102610; Sparrow et al., 2003; un-
published data). Mutations in ACTA1 cause a range of congenital 
myopathies characterized pathologically by nemaline bodies, intra-
nuclear rods, excess actin thin filaments (Nowak et al., 1999), 
fiber type disproportion (small type I fibers; Laing et al., 2004), 
and/or corelike areas (Kaindl et al., 2004). Most patients with 
ACTA1 mutations have severe disease leading to death within 
the first year of life; the most severely affected patients are born 
almost completely paralyzed (Wallgren-Pettersson et al., 2004). 
Therefore, these diseases lead to significant distress for families. 
Determining the ACTA1 mutation responsible for the disease in 
any given family allows accurate diagnosis and the possibility 
of future prenatal or preimplantation diagnosis. However, as the 
majority of mutations are de novo, with families not having any 
family history of the disease (Sparrow et al., 2003), preventing 
new cases arising is elusive. Pursuing therapeutic approaches 
for diseases caused by mutations in ACTA1 is necessary.
Considerable research has been conducted into establish-
ing therapies for skeletal muscle diseases, with most emphasis 
on Duchenne muscular dystrophy (Nowak and Davies, 2004). 
However, many of the approaches investigated for Duchenne mus-
cular dystrophy are not suitable for the congenital myopathies 
caused by mutations in ACTA1 (for example, readthrough of 
nonsense mutations and antisense-induced exon skipping) be-
cause of the paucity of nonsense mutations or the small size and 
lack of possible alternative splicing of ACTA1 (Nowak, 2008). 
Up-regulation of an alternative gene (frequently from the same 
gene family, including fetal isoforms) to compensate for an ab-
sent or defective gene has been successfully used as a treatment 
for diseases in both animal models (Tinsley et al., 1998; Imamura 
et al., 2005; Peter et al., 2008) and humans (Fathallah and Atweh, 
2006). Up-regulation of an alternative gene, another member of 
the actin gene family, may be a possible route to therapy for 
ACTA1 diseases.
ACTA1 (NCBI Protein database accession no. NP_001091) 
is the major protein component of the adult skeletal muscle thin 
filament. It interacts with myosin in the thick filaments during 
muscle contraction, producing the force required for movement. 
ACTC (NCBI Protein database accession no. NP_005150) per-
forms a similar function in the adult heart. The striated muscle 
actins, ACTA1 and ACTC, are in fact coexpressed in heart and 
skeletal muscles. ACTC is the predominant actin isoform in 
fetal skeletal muscle (Ordahl, 1986) but later is down-regulated 
in human skeletal muscle to low levels by birth (Ilkovski et al., 
2005) and accounts for <5% of the striated actin in adult skeletal 
muscle (Vandekerckhove et al., 1986). In vertebrates, ACTA1 
is present in the developing heart and remains up to 20% of the 
striated actin of the adult heart (Vandekerckhove et al., 1986). 
The ACTC and ACTA1 isoforms are 99% identical, varying at 905 RESCUED SKELETAL ACTIN KNOCKOUT MICE • Nowak et al.
whereas the remaining 93.5% survived for >3 mo, with the 
oldest alive beyond 28 mo. Crossing with the low expresser 
ACTC
Cr line resulted in 61% of offspring surviving for 9 d or 
longer (mean age of survival, 12.5 d ± 0.536; maximum age, 
20 d; P < 0.0001). We termed the ACTC
Co/Acta1 KO mice 
ACTC
Co/KO and performed all subsequent experiments with 
these mice.
The absence of ACTA1 but presence of ACTC in skeletal 
muscle from ACTC
Co/KO mice was confirmed by Western blotting 
ACTC expression rescued the lethality of 
Acta1 KO mice
To investigate whether ACTC could replace ACTA1 in skeletal 
muscles,  we  crossed  both  ACTC  transgenic  lines  with  the 
Acta1 KO line in which all homozygous KO mice die by 9 d 
after birth (Crawford et al., 2002). Crossing the higher ex-
pressing ACTC
Co line with the Acta1 KO mice produced 186 
mice null for Acta1 but positive for ACTC. None of these mice 
died within 9 d after birth, 6.5% died between 20 and 52 d, 
Figure 1.  Immunostaining of quadriceps muscle of 7-mo-old ACTC transgenic mice. (A) ACTC staining shows that ACTC
Co mice express more ACTC than 
ACTC
Cr mice. (B) Immunostaining using ACTC and various MHC antibodies on ACTC
Co quadriceps tissue showing that the ACTC transgene is predominantly 
expressed in MHCIIB myofibers. Bars: (A) 50 µm; (B) 100 µm.JCB • VOLUME 185 • NUMBER 5 • 2009   906
quadriceps muscles from ACTC
Co/KO mice had 99.6 ± 0.197% 
ACTC, whereas those from wild-type mice had 4.26 ± 2.57% 
ACTC. Western blotting demonstrated similar amounts of total 
striated muscle -actin in the skeletal muscles of ACTC
Co/KO 
and wild-type mice (Fig. 2 A).
(Fig. 2 A), immunostaining (Fig. 2 B), and flow cytometry 
(Fig. 2 C). Liquid chromatography (LC)/tandem mass spectrom-
etry (MS) multiple reaction monitoring (MRM) MS was used to 
determine the amount of ACTC present as a percentage of the 
total amount of striated -actin (ACTA1 + ACTC) and showed that 
Figure 2.  Protein analyses using specific ACTC 
and  ACTA1  antibodies.  (A)  Western  blotting: 
Coomassie blue staining shows equal loading 
for myosin (220 kD) for all mouse quadriceps 
protein  samples  (lanes  1  and  2  =  wild-type 
CBA/Ca;C57BL/6, lanes 3–5 = ACTC
Cr, lanes 
6–9 = ACTC
Co, lanes 10–13 = ACTC
Co/KO, 
and  lanes  14–16  =  wild-type  FVB/n;CBA/
Ca;C57BL/6). Western blotting was performed 
using antibodies against total actin (all six actin 
isoforms; 42 kD), the striated actin isoforms only 
(both ACTC and ACTA1), ACTC only, or ACTA1 
only. (B) Immunostaining of soleus muscles from 
3-mo-old  male  ACTC
Co/KO  and  wild-type 
mice  using  anti-ACTC  (red  fluorescence)  and 
anti-ACTA1  (green  fluorescence)  antibodies. 
The arrow indicates a muscle spindle positive 
for  ACTC.  Quadriceps,  gastrocnemius,  and 
EDL muscles were also examined and showed 
similar results (not depicted). (C) Representative 
flow  cytometry  of  myofibers  dissociated  from 
the quadriceps muscles of 9-mo-old male wild-
type and ACTC
Co/KO mice and stained using 
anti-ACTC and anti-ACTA1 antibodies (n = 12). 
Gastrocnemius, soleus, and EDL muscles were 
also examined and showed similar results (not 
depicted). Bar, 50 µm.907 RESCUED SKELETAL ACTIN KNOCKOUT MICE • Nowak et al.
Furthermore, there were no differences in measured skeletal 
muscle mitochondrial function (citrate synthase, creatine kinase, 
and complex I) between ACTC
Co/KO and wild-type mice (un-
published data).
Immunostaining with a variety of muscle-specific antibodies 
(Table S1) showed only minor differences in MHC staining, 
which is indicative of altered fiber-type ratios. Myofiber typing 
of EDL muscles (Table II) revealed that ACTC
Co/KO mice had 
more MHCIIX-positive fibers compared with wild-type mice at 
4.5 mo (P = 0.014) and 10 mo (P = 0.038). However, MHCIIX 
fibers were smaller at both time points (P = 0.046 and 0.017, re-
spectively; Table S2). The sum of the percentages for all myosin 
fiber types was >100%, most likely because of the increased 
number of MHCIIB/IIX hybrid fibers in the ACTC
Co/KO mice 
compared with wild-type mice (unpublished data). In the soleus 
muscle (Table II), ACTC
Co/KO mice had more MHCI-positive 
fibers and fewer MHCIIA fibers compared with wild-type mice 
at 4.5 and 10 mo. Fiber sizes were similar between ACTC
Co/KO 
mice and wild-type mice at both time points; only MHCIIA 
fibers were smaller at 4.5 mo (P = 0.008; Table S2).
Skeletal muscle from ACTC
Co/KO mice 
produced slightly less specific force  
than wild-type muscle but had similar  
levels of fatigue
Both the pCa10 value and slope of the pCa–force curves of 
3.5-mo-old skinned EDL fibers were slightly but significantly 
altered for ACTC
Co/KO (pCa10 = 6.36 ± 0.017; slope = 2.55 ± 
0.108) compared with wild-type mice (pCa10 = 6.30 ± 0.014; 
slope = 2.93 ± 0.098; slope, P < 0.05; pCa10, P < 0.005; Fig. 5 A), 
producing a leftward shift of the force–pCa curve. However, 
there was no difference in the pCa50 value, indicating that 
ACTC
Co/KO fibers were more sensitive to lower concentra-
tions of activating Ca
2+. Normalized maximum specific force 
of ACTC
Co/KO skinned EDL fibers was reduced by 25% 
ACTC
Co/KO mice were fertile and produced normal-sized 
litters even when sibs mated. When ACTC
Co/KO females hetero-
zygous  for  the  ACTC
Co  transgene  were  bred  with  ACTC
Co/ 
KO males, approximately one quarter of the offspring died be-
fore 9 d as they were males with no copies of the ACTC
Co trans-
gene, the equivalent of the Acta1 KO mice on the mixed genetic 
background. This suggested the survival of the ACTC
Co/KO mice 
was unlikely the result of the influence of one or more of the 
three background strains.
Homozygous  ACTC
Co/KO  females  were  mated  with 
ACTC
Co/KO males such that a line was created where all off-
spring were negative for Acta1 but homozygous (females) or hemi-
zygous (males) for the ACTC transgene. All offspring from this 
line survived. However ACTC
Co/KO mice weighed significantly 
less than wild-type mice at both 1 and 4 mo of age (Fig. S2). 
ACTC
Co/KO mice at 4–4.5 mo had 60% less white adipose 
tissue relative to body weight when examining perirenal or epi-
didymal fat (P < 0.05; Table I) and 50% less adipose tissue rela-
tive to body weight when comparing the sum of subcutaneous, 
epididymal, and perirenal fat (P < 0.05; Table I). However, 
brown adipose tissue in ACTC
Co/KO mice was not significantly 
different to wild-type mice relative to body weight, nor was 
body mass index (Table I).
Skeletal muscle from ACTC
Co/KO mice was 
similar to wild type
Skeletal muscle of ACTC
Co/KO mice showed no gross abnor-
malities by light microscopy (Fig. 3, A–D). Ultrastructural ex-
amination showed the myofibrillar architecture and sarcomeric 
pattern were retained (Fig. 3, E and F), but occasional focal 
irregularities, breaks and mini-streaming of the Z disc were 
detected. Histochemical analysis of both extensor digitorum 
longus (EDL) and soleus muscles did not show any differences 
in  NADH  and  cytochrome  oxidase/succinate  dehydrogenase 
staining between ACTC
Co/KO and wild-type mice (Fig. 4). 
Table I.  Mass, length, body mass index measurements, and ratios of adipose tissues or EDL muscles to whole-body mass for 5.5-mo-old 
ACTC
Co/KO and wild-type male mice
Measurement Wild type ACTC
Co/KO
Body mass (g) 30.5 ± 0.8 22.2 ± 1.3
a
Body length (cm) 10.0 ± 0.2 8.8 ± 0.2
a
Body mass index 0.30 ± 0.01 0.29 ± 0.01
White adipose tissue
  Total (mg) 602 ± 115 226 ± 23
b
  Subcutaneous (mg) 103 ± 16 80 ± 7
  Epididymal (mg) 431 ± 96 125 ± 15
b
  Perirenal (mg) 68.6 ± 16.7 21.5 ± 1.3
b
Ratio of epididymal + perirenal adipose tissue (g) to body mass (g) 0.0161 ± 0.0034 0.0065 ± 0.004
b
Ratio of white adipose tissue (g) to body mass (g) 0.020 ± 0.003 0.010 ± 0.001
b
Brown adipose tissue (mg) 137 ± 20 91 ± 3
Ratio of brown adipose tissue (g) to body mass (g) 0.0045 ± 0.0007 0.0041 ± 0.0002
EDL mass (mg) 11.1 ± 0.2 12.1 ± 0.3
a
Ratio of EDL mass (mg) to body mass (g) 0.33 ± 0.01 0.40 ± 0.01
a
n = 5 for each group.
aP < 0.005.
bP < 0.05.JCB • VOLUME 185 • NUMBER 5 • 2009   908
ACTC
Co/KO mice did not have a deficit  
in performance
4–6-mo-old male ACTC
Co/KO mice had similar accelerating 
rotarod performance (Fig. 6 A) and grip strength (Fig. 6 B) com-
pared with wild-type mice. However, when the grip strength of the 
ACTC
Co/KO mice was adjusted for body mass, they were 24% 
stronger than wild-type mice with their forelimbs (ACTC
Co/KO = 
3.578 ± 0.1847 g/g; wild type = 2.89 ± 0.1607 g/g; P < 0.05) and 
25% stronger with all of their limbs (ACTC
Co/KO = 5.035 ± 0.1511 
g/g; wild type = 4.04 ± 0.2878 g/g; P < 0.01). Running wheel 
analysis over a 7-d period showed that maximum speed, mean 
speed, time spent running, and distance traveled were not decreased 
compared with wild-type mice (Fig. 6, C–F). In fact, the mean 
speed of ACTC
Co/KO mice was 31% higher than wild-type mice 
(P < 0.01; Fig. 6 C), they ran 105% longer (P < 0.001; Fig. 6 E), and, 
thus, they traveled 148% further (P < 0.001; Fig. 6 F).
Locomotor analysis in an open field test also demonstrated 
that 4–6-mo-old ACTC
Co/KO mice were not negatively affected 
(21.8 ± 1.2 N/cm
2; n = 23) compared with wild-type mice 
(28.9 ± 1.5 N/cm
2; n = 22; P = 0.0007; Fig. 5 B).
Contractility  experiments  were  performed  on  isolated 
EDL muscles from 10-mo-old mice. The characteristics of the 
twitch responses were similar in wild-type and ACTC
Co/KO 
fibers (unpublished data). The relationship between frequency of 
stimulation and force was altered for ACTC
Co/KO muscle com-
pared with wild type, with ACTC
Co/KO muscles producing 
significantly more relative force at 40, 60, 80, and 100 Hz of 
stimulation (Fig. 5 C). Overall maximal force levels of EDL 
muscles were similar for both groups (wild type = 35.0 ± 1.4 g; 
ACTC
Co/KO = 36.7 ± 1.4 g); however, ACTC
Co/KO EDL muscles 
weighed slightly more than wild-type EDL muscles (P < 0.0001; 
Table I). Therefore, maximal specific force was 15% less in 
ACTC
Co/KO muscles (16.4 ± 0.6 N/cm
2) compared with wild-
type muscles (19.3 ± 0.6 N/cm
2; P = 0.004; Fig. 5 D). The sus-
ceptibility to fatigue and rate of recovery were similar for 
wild-type and ACTC
Co/KO muscles (Fig. 5 E).
Figure  3.  Histology  of  skeletal  muscle  from 
male  ACTC
Co/KO  and  wild-type  mice.  (A–D) 
Representative Gomori trichrome (A and B) and 
hematoxylin and eosin (C and D) staining of 
quadriceps  muscle  from  3.5-mo-old  ACTC
Co/
KO  and  wild-type  mice.  (E  and  F)  Electron 
micrographs  of  quadriceps  from  7-mo-old 
ACTC
Co/KO mice. E shows a longitudinal and 
F shows a cross-sectional electron micrograph. 
EDL and soleus muscles were also examined 
and  produced  similar  results  (not  depicted). 
Bars: (A–D) 100 µm; (E and F) 0.5 µm.909 RESCUED SKELETAL ACTIN KNOCKOUT MICE • Nowak et al.
in terms of performance when compared with wild-type mice, 
but, instead, they had greater activity for all of the parameters mea-
sured when compared with wild-type mice (Fig. 7 and Video 1). 
ACTC
Co/KO mice spent 9% more time moving (P < 0.05) and at 
a 41% greater velocity (P < 0.001) than wild-type mice, resulting 
in them traveling 41% further (P < 0.001). ACTC
Co/KO mice also 
reared more often than wild-type mice (by 126%; P < 0.001). At 
older ages, 8–12 mo, when there was no longer a difference in 
weights between the ACTC
Co/KO and wild-type mice, there was 
also no difference in running wheel activity (unpublished data).
Gene expression
Microarray analysis was performed to determine whether the 
presence of cardiac (fetal) actin induced changes in the expres-
sion levels of other muscle proteins, especially other fetal isoforms. 
Analysis of soleus muscles from 11-mo-old ACTC
Co/KO mice 
(see Gene Expression Omnibus accession no. 12882 for all data) 
showed that the expression level of Acta1 was significantly de-
creased (log fold change = 4.7; P = 2.4 × 10
7), whereas that 
of Actc was significantly increased (log fold change = 2.3; P = 
1.9 × 10
4), as expected. The only other fetal skeletal muscle 
genes with altered expression, as measured by microarray analy-
sis, were embryonic MHC3 (Myh3; log fold change = 2.3; P < 
1.6 × 10
4) and embryonic myosin light chain 4 (Myl4; log fold 
change = 0.87; P < 0.005). In spite of this, analysis at the protein 
level with an antibody against Myh3 showed that there was no 
detectable change in Myh3 protein abundance (unpublished data). 
Antibodies against other candidate developmental proteins such 
as utrophin, fetal MHC, and cardiac troponin were used for 
immunostaining: no increase in their expression in ACTC
Co/KO 
skeletal muscle was detected (unpublished data).
Discussion
We created two transgenic mouse lines, ACTC
Co and ACTC
Cr, 
which expressed ACTC in postnatal skeletal muscle. ACTC 
expression in the transgenic lines, despite the use of the slow 
Figure 4.  Enzyme histology of skeletal muscle from male ACTC
Co/KO and 
wild-type mice. (A–H) Representative NADH (A, B, E, and F) and cyto-
chrome oxidase/succinate dehydrogenase enzyme histology (C, D, G, 
and H) of EDL (A–D) and soleus (E–H) muscles from 9-mo-old ACTC
Co/KO 
and wild-type mice. Bars, 100 µm.
Table II.  Percentage of different MHC-typed fibers in EDL and soleus muscles from wild-type and ACTC
Co/KO mice
Age Muscle MHC fiber type Wild type ACTC
Co/KO P-value
mo % %
4.5 EDL MHCIIB 67.04 ± 2.74 61.12 ± 2.97 0.124
4.5 EDL MHCIIX 31.06 ± 2.44 40.38 ± 2.44 0.014
a
4.5 EDL MHCIIA 17.51 ± 1.05 19.64 ± 1.59 0.091
10 EDL MHCIIB 71.10 ± 4.07 74.85 ± 2.54 0.257
10 EDL MHCIIX 25.12 ± 2.40 35.08 ± 3.45 0.038
a
10 EDL MHCIIA 20.32 ± 4.73 13.85 ± 1.80 0.537
4.5 soleus MHCI 46.24 ± 1.21 63.54 ± 3.44 0.0002
b
4.5 soleus MHCIIA 52.91 ± 1.62 40.04 ± 3.37 0.0021
c
10 soleus MHCI 47.03 ± 2.98 74.97 ± 3.15 0.0095
c
10 soleus MHCIIA 49.70 ± 3.20 22.75 ± 2.75 0.0043
c
Muscles were collected from 4.5 (n = 8 or 9)- and 10-mo-old (n = 5) wild-type and ACTC
Co/KO mice and stained with anti-MHCI, anti-MHCIIA, anti-MHCIIB, and 
anti-MHCIIX antibodies. Because of the presence of hybrid fibers expressing more than one MHC type (not depicted), the total percentage of myofibers in the EDL 
muscles of both types of mice is >100%.
aP < 0.05.
bP < 0.001.
cP < 0.01.JCB • VOLUME 185 • NUMBER 5 • 2009   910
less dramatically extended by the ACTC
Cr (low ACTC expresser) 
transgene; 61% survived for >9 d, but the maximum age attained 
was only 20 d old.
The longevity of ACTC
Co/KO mice was unexpected. Others 
have shown that one actin isoform could not substitute or could 
only partially substitute for another. For example, cytoplasmic 
-actin (ACTG1) could not rescue the lethal phenotype of Acta1 
KO mice, although, intriguingly, like our ACTC
Co and ACTC
Cr 
transgenic mice, ACTG1 could incorporate into the thin fila-
ment in transgenic mice and showed no demonstrable detrimen-
tal effect on function (Jaeger et al., 2009). Additionally, two 
thirds of mice with enteric -actin (ACTG2) replacing ACTC in 
the heart died before adulthood (Kumar et al., 1997).
It is interesting to consider the possible reasons why ACTC 
rescued Acta1 KO mice but ACTG1 did not. ACTA1 and ACTC 
differ at only 4 aa residues, whereas ACTA1 and ACTG1 differ 
at 24 aa residues (Fig. S1). ACTC and ACTG2 differ at only 
troponin-I enhancer (Corin et al., 1994), was predominantly in 
MHCIIB fibers (Fig. 2 B), as previously reported with proteins 
expressed under the control of the 2.2-kb human skeletal actin 
promoter alone (Tinsley et al., 1996; Corbett et al., 2001; Jaeger 
et al., 2009). However, in the ACTC
Co/KO mice, ACTC expres-
sion was found in all myofiber types, presumably as a result of 
the absence of ACTA1. Studies have shown that there is a feed-
back mechanism that controls total actin levels so that strict 
stoichiometry of sarcomeric proteins is conserved (Kumar et al., 
2004; Jaeger et al., 2009).
The lethality of the Acta1 KO mice by 9 d of age was 
completely overcome by the ACTC
Co high expressing transgene 
(93.5% survived well into old age). The amount of striated muscle 
actin in the skeletal muscles of the ACTC
Co/KO mice was approx-
imately the same as that in wild-type mice. Thus, complete re-
placement of ACTA1 with ACTC rescued the lethal phenotype 
of the Acta1 KO mice. The lifespan of the Acta1 KO mice was 
Figure 5.  Mouse physiology: individual myofiber and whole-muscle analyses. (A and B) Skinned fiber analysis from EDL muscles from 3.5-mo-old male 
mice (n = 22 wild type; n = 23 ACTC
Co/KO) showing the force–Ca
2+ relationship (A) and normalized maximum force (B). (C–E) Whole EDL muscle contrac-
tile experiments from 10-mo-old male mice (n = 8 for both wild-type and ACTC
Co/KO mice) demonstrating the force–frequency relationship (C), normalized 
maximal force (D), and force loss during fatiguing stimulation and postfatigue recovery (E). Error bars represent ±SEM. *, P < 0.05; **, P < 0.001.911 RESCUED SKELETAL ACTIN KNOCKOUT MICE • Nowak et al.
of functional differences between ACTA1 and ACTC comes 
from the hearts of BALB/c mice, which, because of a mutation 
of the ACTC promoter, have reduced levels of ACTC and   
increased levels of ACTA1 (Jackaman et al., 2007). The hearts 
of BALB/c mice are hypercontractile (Hewett et al., 1994), sug-
gesting ACTA1 generates greater force in interacting with myosin. 
Nevertheless, from our results, myosin and ACTC interactions 
generate sufficient force in the skeletal muscle sarcomere for 
survival, whereas ACTG1 does not.
We do not know the precise reasons for the reduced weight 
and size of the ACTC
Co/KO mice during their early months. The 
difference at 1 mo must be a developmental effect and may be 
caused by the fact that the transgene is normally preferentially 
expressed in MHCIIB fibers or by the absence of ACTA1 in the 
developing heart or other tissues. The weight difference, includ-
ing the reduction in adipose tissue, at 4 mo is probably the result 
seven residues (Fig. S1), but it has been shown that two of those 
differences significantly alter the interaction of the actin iso-
form with myosin (Mossakowska and Strzelecka-Golaszewska, 
1985). In the same experiments, it was shown that the inter-
action of ACTC and ACTA1 with myosin were indistinguishable 
(Mossakowska  and  Strzelecka-Golaszewska,  1985). Analysis 
of isolated myofibrils from cardiac muscle demonstrated a four-
fold reduction in force generation compared with isolated myo-
fibrils from skeletal muscle (Linke et al., 1994). However, these 
differences in force generation cannot entirely be attributed to 
the roles of ACTA1 and ACTC, as cardiac myofibrils also differ 
from skeletal muscle in other sarcomeric proteins such as tropo-
nins and tropomyosin, and a previous study has shown that 
cardiac and skeletal muscle troponin and tropomyosin isoforms 
show differences in their ability to interact with ACTA1 and 
myosin (Clemmens et al., 2005). Perhaps the clearest indication 
Figure 6.  ACTC
Co/KO mice perform as well as or better than wild-type mice (and other genotypes tested) for grip strength, rotarod, and running wheel 
tests. (A–F) Mouse performance is given as measured by rotarod (A), grip strength (B), and running wheel analysis (mean speed [C], maximum speed [D], 
time spent running [E], and distance traveled [F]). n = 10, 11, or 12 for all groups of male 4–6-mo-old mice. Error bars represent ±SEM. *, P < 0.05; and 
**, P < 0.001 when ACTC
Co/KO mice were compared with all other genotypes.JCB • VOLUME 185 • NUMBER 5 • 2009   912
the presence of ACTC as the sole striated muscle -actin in 
skeletal muscle after birth has little influence on the levels of 
other muscle proteins, including other fetal proteins.
The ACTC
Co/KO mice measured at 4–6 mo of age were 
not impaired in grip strength, rotarod, or locomotor activity. 
Despite our hypothesis that ACTC might replace ACTA1 suffi-
ciently to allow for a significant increase in survival of the 
resulting mice, we expected that some of these parameters of 
muscle function would be suboptimal, given the high evolu-
tionary conservation of these two striated actins. However, 
ACTC
Co/KO mice surprisingly showed increased activity com-
pared with wild-type mice, for several parameters, but we can-
not rule out entirely that genetic differences other than the 
substitution of ACTA1 by ACTC are the cause of the increased 
activity. Nevertheless, the evidence remains that ACTC can 
function adequately in skeletal muscle during increased exer-
cise. The large increase in the amount of voluntary exercise 
that the ACTC
Co/KO mice exhibited may be the cause of the 
focal Z-disc abnormalities visualized by electron microscopy as 
such changes have been reported in endurance athletes (Grobler 
et al., 2004).
Among the severely affected patients with ACTA1 muta-
tions are those lacking ACTA1 as the result of homozygous null 
mutations (Nowak et al., 2007). Most of these patients were born 
severely affected, with three out of seven patients requiring me-
chanical ventilation from birth (Nowak et al., 2007). The patient 
with the best clinical outcome had the highest level of ACTC 
in skeletal muscle (Nowak et al., 2007). Thus, the ACTA1-null 
patients may be overall more the equivalent of the ACTC
Cr/KO 
mice than the ACTC
Co/KO mice. Therefore, our data indicate 
that ACTA1-null patients may benefit if the levels of ACTC in 
their skeletal muscles could be further increased. Experiments to 
ascertain whether ACTC expression can sufficiently dilute the 
effects of mutant ACTA1 proteins are presently being performed, 
of, at least in part, the greater spontaneous activity of the ACTC
Co/
KO mice at this stage. The absence of a statistically significant 
difference in weight and running wheel activity later might in-
dicate that the early differences may be more caused by effects 
outside of the muscle itself. For example, it is known that ACTA1 
is expressed in the brain (Bertola et al., 2008), but its function 
there is unknown.
The skeletal muscle in the ACTC
Co/KO mice overall ap-
peared normal by standard histology and electron microscopy. 
Some minor variations in myosin fiber types were observed in 
both the EDL and soleus of the ACTC
Co/KO mice at both 4.5 
and 10 mo of age (Table II), which may have been as a result of 
the increased activity of the ACTC
Co/KO mice. However, there 
was no alteration in the levels of mitochondrial enzymes com-
pared with wild-type mice (unpublished data). Previous studies 
have shown that myosin fiber types can alter without changing 
the levels of mitochondrial enzymes (for review see Spangenburg 
and Booth, 2003).
Although  EDL  muscles  from  ACTC
Co/KO  mice  were 
larger than those from wild-type mice, this was not caused by 
hypertrophied muscle fibers or an increase in interstitial fat or 
connective tissue, as is seen with many muscular dystrophies. 
Despite the normalized maximum specific force for EDL mus-
cles from ACTC
Co/KO mice being less than wild-type mice, the 
overall force (taking into account the larger size of the EDL 
muscles) was equivalent. The increase in EDL size might be a 
compensatory mechanism.
Despite the exchange of ACTA1 with the fetal/cardiac 
striated actin ACTC, no increases in the levels of the other fetal 
or cardiac proteins tested were detected by immunostaining. By 
microarray  analysis,  the  transcriptional  levels  of  Myh3  and 
Myl4 were significantly changed, but this could not be con-
firmed at a protein level for Myh3 (Myl4 could not be tested be-
cause of the lack of a specific antibody). Thus, it appears that 
Figure 7.  ACTC
Co/KO mice are more active 
than  wild-type  and  other  mice.  (A–D)  Loco-
motor  activity  over  30  min  was  measured, 
including  distance  traveled  (A),  time  spent 
moving (B), number of rearings (C), and mean 
speed (D). n = 10, 11, or 12 for all groups 
of male 4–6-mo-old mice. Error bars represent 
±SEM. *, P < 0.05; and **, P < 0.001 when 
ACTC
Co/KO mice were compared with wild-
type mice.913 RESCUED SKELETAL ACTIN KNOCKOUT MICE • Nowak et al.
(model 2100; JEOL), and images were taken with an 11-megapixel digital 
camera (SC100 Orius; Gatan, Inc.).
Western blotting
Protein extraction and Western blotting were performed essentially as pre-
viously outlined (Nowak et al., 2007). Total protein levels were measured 
using the bicinchoninic acid detection kit (Thermo Fisher Scientific), and 1 
µg per sample was loaded onto NuPage Novex 4–12% Bis Tris gels (Invit-
rogen). One gel was stained by Coomassie dye, and then the myosin 
bands were compared for intensity. Replicate gels were transferred onto 
polyvinylidene fluoride membranes using Towbin’s transfer buffer (25 mM 
Tris, 192 mM glycine, and 20% methanol) at 300 mA for 2 h at RT. Mem-
branes were blocked for 1 h at RT in blocking buffer (5% skim milk pow-
der in PBS and 0.1% Tween 20) and then incubated with one of the 
appropriate primary antibodies (concentrations given in Table S1) over-
night at 4°C in blocking buffer. Membranes were washed three times for 
5 min with 0.1% Tween 20 and PBS before 1-h incubations with corre-
sponding secondary antibodies (either HRP-conjugated goat anti–rabbit 
[clone  A0545;  Sigma-Aldrich]  or  HRP-conjugated  rabbit  anti–mouse 
[clone A9044; Sigma-Aldrich]), both at 1:10,000. After another set of 
three 5-min washes, the membranes were incubated for 5 min in ECL Plus 
detection reagent (GE Healthcare) and then visualized by a ChemiDoc 
XRS HD System (Bio-Rad Laboratories), with densitometry of ACTC-posi-
tive bands and Coomassie-stained MHC bands performed using PDQuest 
software (Bio-Rad Laboratories).
MS
LC/tandem  MS  MRM  MS  was  performed  as  previously  described   
(Ravenscroft et al., 2008). In brief, total protein was extracted from the 
quadriceps from 6-mo-old male wild-type (n = 3) and ACTC
Co/KO (n = 6) 
mice and then resolved by denaturing SDS-PAGE. After Coomassie staining, 
proteins of the approximate size for actin (from 30 to 50 kD, as actin is 
42 kD) were excised from the gel, extracted, and digested using trypsin and 
analyzed by LC/tandem MS MRM MS. Peptides either present in both ACTC 
and ACTA1 proteins or specific for ACTC or ACTA1 were used to calculate 
the proportion of ACTC or ACTA1 of the total striated actin pool.
Flow cytometry
Muscle flow cytometry was performed as previously described (Jackaman 
et al., 2007). In brief, muscle samples were incubated for 30 min in   
collagenase/dispase mix (each 1 mg/ml; Sigma-Aldrich) at 37°C and 
then prepared as a single-cell suspension by gentle dispersion using frosted 
glass slides followed by trituration with a Pasteur pipette. Samples were 
fixed in 2% paraformaldehyde for 15 min on ice and permeabilized in 
PBS, 10% FCS, 1% BSA, and 0.5% saponin (Sigma-Aldrich). Anti-ACTC 
antibody (conjugated to Zenon-XX-Biotin; Invitrogen) and anti-ACTA1 anti-
body were incubated overnight at 4°C. Streptavidin–R-phycoerythrin (Jackson 
ImmunoResearch Laboratories) and anti–rabbit–Alexa Fluor 488 (for the 
ACTA1 antibody; Invitrogen) were incubated for 60 min on ice. Control 
suspensions of relevant isotype controls, no stains, and single stains were 
used to determine the settings for the FACSCalibur (BD).
Mitochondrial isolation
Muscle homogenates and mitochondria isolated from muscle were pre-
pared principally as described previously (Frezza et al., 2007). Minced 
muscles were placed into 0.5% trypsin-EDTA in PBS for 30 min on ice, after 
which they were centrifuged at 200 g for 5 min at 4°C. The supernatant 
was removed, and the pellets were resuspended in 67 mM sucrose, 50 mM 
Tris-HCl, 50 mM KCl, 10 mM EDTA, and 0.2% BSA, pH 7.4, and then 
further homogenized by passing through a 70-µm nylon cell strainer. To 
isolate mitochondria, muscle homogenates were centrifuged at 700 g for 
10 min at 4°C, and the supernatant was further centrifuged at 8,000 g for 
10 min at 4°C. The supernatant was discarded, and the pellet was re-
suspended in 250 mM sucrose, 3 mM EGTA, and 10 mM Tris/HCl, pH 7.4. 
The samples were centrifuged at 8,000 g for 10 min at 4°C before the pel-
let was resuspended in 150 µl of this same buffer and then kept on ice. 
Mitochondria were then used to perform assays assessing citrate synthase, 
complex I, and creatine kinase activity. Statistical analyses were performed 
using Student’s two-tailed t test with equal variance.
Skinned fiber analysis
The contractile properties of the myofilaments were characterized using 
single, mechanically skinned fibers from the EDL muscles of male 3.5-mo-
old ACTC
Co/KO and wild-type mice. Isometric force was measured with a 
sensitive force transducer (SI Heidelberg). Data were acquired using a 
as most patients with ACTA1 disease have dominant rather than 
null mutations (Sparrow et al., 2003).
Our results demonstrate that ACTC can effectively replace 
ACTA1 in postnatal skeletal muscle. Further analysis of the 
ACTC
Co/KO mice will allow exploration of the precise func-
tional differences between ACTA1 and ACTC that have led to 
the evolutionary development of two such similar striated mus-
cle actins and perhaps, in time, explain their alternating expres-
sion during development.
Materials and methods
Mouse lines
All animal procedures were approved by the Animal Experimentation 
Ethics Committee of the University of Western Australia. We created two 
transgenic  mouse  lines  according  to  standard  protocols  (Tinsley  et  al., 
1996) on a C57BL/6J;CBA/Ca background, namely C57BL/6J;CBA/
Ca-Tg(ACTC)CoKno (ACTC
Co; laboratory nickname “Coco”) and C57BL/
6J;CBA/Ca-Tg(ACTC)CrKno  (ACTC
Cr;  laboratory  nickname  “Crosby”). 
These lines expressed the human ACTC gene (identical to murine at the 
amino acid level) under the control of a 2.2-kb fragment of the human skel-
etal muscle -actin (HSA) promoter (Brennan and Hardeman, 1993) and 
the troponin-I slow upstream enhancer (both provided by E. Hardeman, 
University of New South Wales, Sydney, New South Wales, Australia; 
Corin et al., 1994).
To generate mice lacking Acta1 but expressing an ACTC transgene, 
male hemizygous Acta1 KO mice (FVB/n background) were bred with 
female heterozygous ACTC transgenic mice from each ACTC transgenic 
line. F1 offspring hemizygous for Acta1 and heterozygous for the ACTC 
transgene were bred together to produce mice negative for Acta1 but hav-
ing one or two copies of the ACTC transgenes. All wild-type control ani-
mals were the mice resulting from the F1 cross homozygous for the wild-type 
Acta1 allele but without a copy of the ACTC transgene and were thus on 
the same (FVB/n;C57BL/6J;CBA/Ca) genetic background.
The  presence  of  either  ACTC  transgene  was  determined  using 
primers specific for the HSA promoter (HSA forward, 5-GATGAACTGC-
CATGATGTG-3; and HSA reverse, 5-TAGATGAGGCTTAGCTGGTC-3). 
Genotyping for the Acta1 wild-type and KO alleles was performed using 
three primers, two flanking the insertion site of the KO PGK1 cassette (Acta1 
intron 1 forward, 5-GCAGCGTGCCTTAATACCTC-3; and Acta1 intron 
2 reverse, 5-CCTGCAGATAGAGACATCAG-3) and the third within the 
PGK1 cassette itself (PGK1 reverse, 5-TCCATCTGCACGAGACTAGT-3).
Histology, immunostaining, fiber typing, and morphometry
10-µm cryostat sections were stained for basic morphology and histology 
using  standard  techniques  (Dubowitz  and  Sewry,  2007).  Immunohisto-
chemistry was performed as previously described (Jackaman et al., 2007). 
In brief, mouse IgG1 antibodies (Table S1) were conjugated to Zenon re-
agents (mouse IgG1 Alexa Fluor 350, 488, or 594; Invitrogen) and incu-
bated overnight at 4°C. IgM or rabbit IgG antibodies were incubated 
overnight at 4°C followed by secondary antibodies anti–mouse IgM–Alexa 
Fluor 488 (Invitrogen) or anti–rabbit–Alexa Fluor 488 (Invitrogen) for 45 
min at RT. All slides were mounted in Hydromount (National Diagnostics) 
for subsequent imaging. Images were taken at RT on a fluorescent micro-
scope (IX-71; Olympus) equipped with 20× NA 0.45 and 40× NA 0.60 
objective lens using a digital camera (DP-71; Olympus) with DP Controller 
and Manager software (Olympus).
Fiber diameter was determined as the shortest distance through the 
center of the fiber (Briguet et al., 2004). The proportion of fibers positive 
for each MHC type was calculated as the percentage of positive fibers of 
the total fibers from two random fields containing 100 fibers per field. 
Because of small group sizes, the Mann-Whitney test was used for statisti-
cal analysis with a 95% confidence interval.
Electron microscopy
Excised samples were placed into fixative (2.5% cacodylate-buffered glutar-
aldehyde), osmicated, dehydrated in progressive alcohols and propyl-
ene oxide, and embedded in resin. Ultrathin sections were cut using an 
ultramicrotome (LKB 8800; Bromma), placed onto 150 mesh copper grids, 
and stained with acidified uranyl acetate, saturated uranyl acetate, and finally 
lead citrate. Grids were viewed using a transmission electron microscope JCB • VOLUME 185 • NUMBER 5 • 2009   914
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PowerLab data acquisition system (ADInstruments). To maximize the force 
production, the fibers were stretched from slack length by 20% (Han and 
Bakker, 2003). The sensitivity of the contractile apparatus to Ca
2+ and 
maximal force production was determined by exposing the skinned fibers 
to solutions of different free Ca
2+ concentrations.
Whole-muscle analysis
Excised EDL muscles from 10-mo-old male mice were suspended in a verti-
cal organ bath connected to a force transducer (1200 A; Intact Muscle Test 
System; Aurora Scientific, Inc.). The organ bath contained carbogen (5% 
CO2 in oxygen) and bubbled Ringer solution (137 mM NaCl, 24 mM 
NaHCO3, 11 mM glucose, 5 mM KCl, 2 mM CaCl2, 1 mM NaH2PO4, and 
1 mM MgSO4) and was maintained at 25°C. The dynamic properties of 
twitch response, the force–frequency relationship, susceptibility to fatigue, 
and rate of postfatigue recovery were all measured.
Phenotypic tests
Male mice were analyzed at the Integrated Neuroscience Facility (http://
www.hfi.unimelb.edu.au/inf) for motor function according to their stan-
dard protocols. At least 10 mice from each of the five different genotypes 
in the age range from 4 to 6 mo were tested for grip strength, rotarod, and 
voluntary running wheel performance. Prism 4 software (GraphPad Software, 
Inc.) was used to conduct one-way analyses of variance of the phenotypic 
data followed by a Bonferroni post-hoc test.
Statistics
Data are presented as the mean ± SEM. Prism 4 was used to conduct two-
tailed t tests for all statistical analyses, except for the force–frequency and 
fatigue datasets. Multivariate analysis of variance was conducted using 
Statistica (StatSoft Pacific Pty. Ltd.) with main effects of genotype and re-
peated measures of frequency and time for the force–frequency and fa-
tigue datasets, respectively. When the multivariate analysis of variance 
indicated significant main effects and interaction, individual means were 
compared with a Student-Newman-Keuls post-hoc test.
Online supplemental material
Fig. S1 shows a comparison of the amino acid sequences of the six human 
actins. Fig. S2 shows a comparison of the weights of the ACTC
Co/KO and 
wild-type mice at 1, 4, 7, 12, and 18 mo. Video 1 shows 1-yr-old ACTC
Co/KO 
and wild-type mice. Table S1 shows the antibodies used in this study. Table 
S2 shows the sizes of MHC-typed myofibers from wild-type and ACTC
Co/
KO mice at 4.5 and 10 mo of age. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200812132/DC1.
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